Welcome back to this November 2026 run-through of Dermatologic Surgery. We've got four pieces to get through this episode — a nasal bolster technique pearl, two reconstructive conundrums from the ear and the lip, and a claims-based look at Mohs utilization and reimbursement trends in the Medicare population. Let's get into it. First up is a "How We Do It" piece describing a syringe plunger as a bolster dressing for full-thickness skin grafts, specifically on the nasal ala. The clinical problem here is one every Mohs surgeon knows intimately — a full-thickness skin graft on the ala gives you reliable coverage and preserves the alar groove contour, but the classic Blair-Brown tie-over bolster is awkward to secure in this location, and if you cinch it down too aggressively you risk collapsing the nostril. Several workarounds for this have already been described in the literature, and this group adds another one to the toolbox. The technique itself is refreshingly low-tech. After harvesting and defatting a full-thickness graft from the preauricular skin and securing it with simple sutures, they take two 3-milliliter syringes, pop off the rubber plunger tips with a hemostat, and use those tips as the bolster material. A transfixing 4-0 nylon U-suture is passed through an external plunger tip, the graft, the native ala, and an internal plunger tip, then back in the reverse direction — essentially sandwiching the graft and the cartilage between two rubber discs. A secondary gauze dressing goes over the top, the bolster stays in place for a week, and graft sutures come out at two weeks. They report complete graft take. The rationale the authors give is mechanical — bolsters work by applying uniform pressure to eliminate dead space and keep the graft in intimate contact with the wound bed, which supports the sequence of imbibition, inosculation, and neovascularization that a graft depends on for survival. What the syringe plunger buys you over a standard tie-over is a rigid, compact, reproducibly sized pad that's cheap, sterile, hypoallergenic, and doesn't stick to the graft — and critically, its rigidity distributes pressure evenly without the kind of focal cinching that collapses a nostril. They're candid that the evidence base comparing tie-over dressings to alternatives like quilting sutures or simple pressure dressings is thin across the board, so this isn't being sold as proven superior, just as a practical, low-cost option worth having in your kit. Practically speaking, this is a nice-to-have rather than a practice-changer — it's not going to alter your reconstructive algorithm, but it's an easy, free modification using supplies already sitting in your procedure room, and it's worth trying the next time you're wrestling with bolster fixation on an alar graft. Next is a Reconstructive Conundrum piece, which walks through a genuinely tricky ear defect rather than presenting original data, so I'll take it through the case, the options considered, and the technique as the authors laid it out. A 72-year-old man on apixaban, with a history of multiple myeloma and a prior melanoma, underwent three stages of Mohs for a squamous cell carcinoma on the superior helix. The final defect was about two and a half by two centimeters, full thickness through the helical rim and groove, and extending into the scapha — so you're missing both the three-dimensional tubular structure of the helix and the adjacent flat scapha cartilage and skin. The author walks through why each standard option falls short. A wedge excision causes cupping and loss of vertical ear height, which the patient didn't want. The Antia-Buch chondrocutaneous advancement flap is a workhorse for mid-helical defects but doesn't reach large defects and wouldn't reconstruct the scapha at all. A second advancement flap from the helical root was considered but wouldn't gain enough length, especially given this patient's lack of lobule laxity. A Davis flap was rejected because the distance from the conchal bowl donor site to the scapha defect risked ischemia and would bow the ear, and an Orticochea flap wouldn't recreate the tubular three-dimensional rim. Retroauricular or mastoid interpolation flaps alone could rebuild the scapha but not the prominent tubular rim. The solution was to combine two interpolation flaps from the mastoid region in an over-under configuration — a tubed interpolation flap to recreate the helical rim and groove, stacked over a retroauricular interpolation flap to reconstruct the scapha. Technically, the tubed flap was designed at one and a half centimeters wide, elevated bipedicled in the subcutaneous plane, thinned to roughly two millimeters of fat, and folded on itself into a tube — leaning on the fact that tubed flaps tolerate length-to-width ratios up to six-to-one given their robust blood supply. The retroauricular flap was then advanced underneath to resurface the scapha. This was staged across three surgeries roughly three weeks apart: division and inset of the tubed flap's superior end with V-Y closure at stage two, then division and inset of the inferior end at stage three. There was a postoperative hemorrhage after stage one requiring surgical intervention, but no flap ischemia at any point, which the author highlights as a testament to the flap's robustness even after aggressive thinning. The discussion emphasizes that the over-under configuration kept the construct low-profile between stages — the patient was golfing between stages two and three — which addresses the usual complaint that interpolation flaps are cumbersome for patients to live with while pedicled. Downsides acknowledged are the three-stage commitment and the need to deal with transferred hair-bearing skin, which can be managed with laser hair removal. At seven months the ear had good symmetry with the contralateral side. The takeaway here is conceptual rather than something you'll reach for every week: for compound helical defects that need both tubular rim and flat scapha restored, two interpolation flaps can be stacked in an over-under fashion rather than treating the defect as a single reconstructive problem. Worth filing away for the rare large compound ear defect that doesn't fit the usual single-flap solutions. The third piece is another Reconstructive Conundrum, this time on the lip. A 78-year-old man had a basal cell carcinoma cleared in two stages from the philtrum, leaving a defect of about two by one and a half centimeters involving the lower philtral cutaneous lip, the philtral ridges, Cupid's bow, and adjacent vermilion. The author runs through why this is a deceptively hard defect: you have to respect both the concavity of the philtrum and the convexity of Cupid's bow, which is a projecting, not a flat, landmark. Secondary intention would likely leave eclabium. A full-thickness skin graft would require sacrificing the residual philtral unit and still leave you reconstructing the vermilion separately, with an inevitable mismatch in skin texture and color. Island pedicle flaps from the remaining philtrum and columella are a standard option but typically need secondary thinning to recreate the philtral concavity, since the flap's own pedicle sits right where that concavity should be — a pincer flap modification helps somewhat but doesn't fully solve it. Abbe switch and Karapandzic flaps were dismissed as overkill for a defect this shallow. The chosen solution was bilateral hatchet flaps designed along the philtral crests with advancing back cuts, undermined at the sub-SMAS plane just above orbicularis, with a superior pedicle preserved at the columella. The back cuts let the philtral remnant advance inferiorly, recreating Cupid's bow, and a pexing suture from the flap underside to the deep orbicularis helped secure that inferior movement and maintain contour. The vermilion defect was closed separately with bilateral vermilion rotation flaps advanced medially from near the commissures. The author notes that in a younger or more cosmetically demanding patient, a dermal graft or orbicularis hinge flap could be added under the vermilion flaps to replace lost muscle volume, but it wasn't necessary here. This achieved a single-stage repair with no revision needed, and the six-month result preserved the key anatomic landmarks — philtral concavity and Cupid's bow convexity — without needing a second procedure. The practical lesson is about matching flap design to the specific topography of the lip: cutaneous lip gets reconstructed with cutaneous lip tissue and vermilion with vermilion tissue, incisions get hidden along the vermilion-cutaneous junction or philtral crests, and back-cut advancement flaps can be tuned to recreate a specific convexity like Cupid's bow simply by controlling the width of the back cut. This is a solid single-stage alternative to island pedicle flaps worth keeping in mind for shallow-to-moderate philtral defects, particularly when you want to avoid a secondary thinning procedure. Last up is an original, data-driven piece — a retrospective analysis of Mohs micrographic surgery utilization and reimbursement in the Medicare population from 2018 through 2022. The gap the authors identify is straightforward: Medicare enrollment, skin cancer incidence, and dermatologic procedure volume have all been climbing, but there's been limited recent work specifically tracking Mohs utilization and payment patterns, especially broken down by geography, despite the fact that Medicare payment itself varies regionally. Methodologically, this is a retrospective analysis built entirely on publicly available CMS data — the Medicare Physician and Other Practitioners data sets and CMS Program Statistics — covering CPT codes 17311 through 17315, with the base codes 17311 and 17313 used to isolate individual procedures. This is exactly the kind of question a retrospective registry design suits well: you're not testing an intervention, you're characterizing a national trend over time using data nobody needed to prospectively collect, so a claims-based descriptive approach is the only practical way to answer it at this scale. They looked at overall trends plus breakdowns by year, state, and the four census regions, and all dollar figures were inflation-adjusted to January 2022. The one inferential step here is a multivariate linear regression on the 2022 data, used to identify predictors of procedural volume at the state level. This is worth pausing on because it's a good teaching example. A simple descriptive comparison — say, just ranking states by volume — can't tell you whether higher volume in a state is because that state has more Mohs surgeons, more eligible Medicare beneficiaries, or some other factor, because all of these things move together. Multivariate linear regression lets you put several predictors into the same model simultaneously and estimate each one's independent contribution to procedural volume while holding the others constant — mathematically, it's fitting a best-fit linear relationship between the outcome and each predictor, with the regression coefficient for a given variable representing how much procedural volume changes when that variable shifts, after accounting for the other variables in the model. That's what let them conclude that the number of providers in a state was a significant and independent predictor of volume, whereas the number of eligible Medicare enrollees only approached significance, without those two correlated variables confounding each other's effect. On to the key results. Between 2018 and 2022, there were about one hundred twelve thousand more individual Mohs surgeries performed nationally, a roughly 12 percent increase, translating to about 53 additional procedures per hundred thousand Medicare beneficiaries — a real, clinically meaningful growth in volume, not a statistical artifact. The South had the highest absolute procedure volume overall, led by Florida and Texas, while the West saw the largest percentage increase, driven mainly by California and Arizona. At the state level, New Mexico had the single largest percentage change in volume, with New Hampshire and Wyoming also showing notable shifts in provider numbers. Meanwhile, the proportion of cases requiring more than five stages decreased across every region, most prominently in the Midwest. On the payment side, using CMS standardized payment amounts — which strip out geographic and facility-type adjustments to allow apples-to-apples comparison — the South led reimbursement across nearly every relevant CPT code. But the headline finding is that overall Medicare reimbursement for Mohs fell by about 12 percent cumulatively over this five-year window, with the steepest declines for the primary codes, 17311 and 17313, occurring in the Midwest. In their discussion, the authors connect the drop in high-stage cases to the American College of Mohs Surgery's Improving Wisely initiative, a peer-to-peer audit and feedback intervention aimed at curbing overuse of high-stage Mohs, which rolled out right around the start of this study period — a plausible explanation, though this is an ecological, population-level association rather than something this data set can directly prove caused the shift. The reimbursement decline, meanwhile, is attributed to cuts in the Medicare Conversion Factor in 2021 and 2022, compounded by the simple fact that Medicare payment updates haven't kept pace with inflation. The obvious limitation here is that this is aggregate, publicly available claims data — there's no patient-level clinical detail, no ability to adjust for case complexity beyond the stage-count proxy, and the regression is cross-sectional on a single year rather than tracking change over time, so it tells you about correlates of volume in 2022, not causes of the five-year trend. It's also Medicare-only, so it says nothing about commercially insured or self-pay patients, who make up a substantial share of many Mohs practices. For practical takeaways, this one is more context than action item for an individual surgeon's technique, but it is genuinely relevant to practice management and advocacy. Falling reimbursement per procedure despite rising volume is a trend worth watching closely if you're involved in practice finances or coding advocacy, and the regional variation — particularly the Midwest seeing both the steepest reimbursement declines and the steepest drop in high-stage cases — is worth knowing if you're benchmarking your own practice patterns or evaluating staffing and provider recruitment in a given region. The decline in high-stage procedures nationally is reassuring as an indirect marker that peer feedback interventions around appropriate use may be having a measurable effect, though that link remains associative rather than proven. That wraps up this November issue — a clever bolster hack for alar grafts, two elegant solutions to compound ear and lip reconstructions, and a sobering look at where Mohs reimbursement is headed nationally. Thanks for listening, and I'll see you next month.